This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Road safety risks associated with medicinal cannabis appear similar or lower than numerous other potentially impairing prescription medications. The Lambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney, Sydney, NSW 2050, Australia.
The Lambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney, Sydney, NSW 2050, Australia. Road safety risks associated with medicinal cannabis appear similar or lower than numerous other potentially impairing prescription medications. Road safety. Medicinal cannabis. Drug driving.
Patient associations estimate that we’ll have around 1,5 million people suffering from Alzheimer in Spain by 2050. They protect neurons – although many media state the opposite – since cannabinoids are not neurotoxic (compared to alcohol, nicotine and some medicines). Source: Spanish Society of Neurology ).
It is worth noting that Marinol ® (dronabinol) is an FDA-approved synthetic cannabinoid that was placed in Schedule III under the CSA in 1999.). 2050 , 2051, 2075; Pub. Preventing the growing of marijuana on public lands and the attendant public safety and environmental dangers posed by marijuana production on public lands; and. .
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content